Loading patent…
AssigneeThe Whittier Institute for Diabetes and Endocrinology
InventorsAnn Logan, Andrew Baird
Estimating the term…
The present invention relates to methods for preventing, suppressing or treating a CNS pathology characterized by a deleterious accumulation of extracellular matrix in a tissue by contacting the tissue with an agent that inhibits the extracellular matrix producing activity of TGF-.beta.. The methods can be used to prevent, suppress or treat scar formation in the CNS. Agents that are useful in the present methods include neutralizing anti-TGF-.beta. antibodies, Arg-Gly-Asp-containing peptides, decorin and its functional equivalents such as biglycan, and TGF-.beta. antagonists. The present invention further provides methods for preventing, suppressing or treating a CNS pathology characterized by the insufficient accumulation of extracellular matrix. Agents that enhance the production of extracellular matrix, such as TGF-.beta., can be used in such methods. Finally, the present invention provides pharmaceutical compositions containing these agents, which can be administered to patients to inhibit or enhance the production of extracellular matrix in the CNS.
A method useful for suppressing a deleterious accumulation of extracellular matrix in a tissue of the central nervous system, comprising administering to the tissue an agent that binds to TGF-.beta. and that inhibits the extracellular matrix producing activity of TGF-.beta. in an amount effective to inhibit extracellular matrix accumulation.
A method useful for suppressing scar formation in a lesion of central nervous tissue comprising administering to the tissue an agent that inhibits the extracellular matrix producing activity of TGF-.alpha., wherein said agent is decorin, biglycan, fibromodulin or a neutralizing anti-TGF-.beta. antibody, in an amount effective to inhibit extracellular matrix accumulation.
Dependencies are inferred from the claim text.